5 results on '"Keklik, Muzaffer"'
Search Results
2. Evaluation of COVID-19 fear and quality of life in patients with haematopoietic stem cell transplantation during the COVID-19 pandemic.
- Author
-
Çelik S, Güven ZT, İpekten F, Keklik M, Ünal A, and Kaynar L
- Subjects
- Fear psychology, Humans, Pandemics, Prospective Studies, Quality of Life, COVID-19 epidemiology, Hematopoietic Stem Cell Transplantation
- Abstract
Objective: We aimed to determine the coronavirus disease 2019 (COVID-19) fear state in haematopoietic stem cell transplant patients and to examine its relationship with quality of life., Methods: In this prospective study, 64 patients who underwent HSCT during the pandemic were included. The COVID-19 fear situation was evaluated with the Fear of COVID-19 Scale (FCV-19S). Quality of life was evaluated with the European Organisation for Quality of Life Research and Treatment Core Questionnaire (EORTC QLQ-C30) (Version 3)., Results: The median FCV-19S score was 16.5 (12.0-22.0). The FCV-19S score was significantly higher in urban residents than rural residents. The general health score was 59.64 ± 20.04. The strongest positive correlation between fear level and life quality was found in emotional function. A weak, significant, positive correlation was observed between role function, nausea-vomiting, pain, appetite loss and fear level., Conclusion: FCV-19S is a quick, safe and valid tool that can be used to determine the COVID-19 fear level in vulnerable patient groups such as HSCT patients and to direct them to the necessary psycho-oncological support., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
3. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
- Author
-
Civriz Bozdağ S, Cengiz Seval G, Yönal Hindilerden İ, Hindilerden F, Andıç N, Baydar M, Aydın Kaynar L, Toprak SK, Göksoy HS, Balık Aydın B, Demirci U, Can F, Özkocaman V, Gündüz E, Güven ZT, Özkurt ZN, Demircioğlu S, Beksaç M, İnce İ, Yılmaz U, Eroğlu Küçükdiler H, Abishov E, Yavuz B, Ataş Ü, Mutlu YG, Baş V, Özkalemkaş F, Üsküdar Teke H, Gürsoy V, Çelik S, Çiftçiler R, Yağcı M, Topçuoğlu P, Çeneli Ö, Abbasov H, Selim C, Ar MC, Yücel OK, Sadri S, Albayrak C, Demir AM, Güler N, Keklik M, Terzi H, Doğan A, Yegin ZA, Kurt Yüksel M, Sadri S, Yavaşoğlu İ, Beköz HS, Aksu T, Maral S, Erol V, Kaynar L, İlhan O, Bolaman AZ, Sevindik ÖG, Akyay A, Özcan M, Gürman G, Ünal Ş, Yavuz Y, Diz Küçükkaya R, and Özsan GH
- Subjects
- Adult, Amides administration & dosage, Azithromycin administration & dosage, Child, Humans, Hydroxychloroquine administration & dosage, Hydroxychloroquine adverse effects, Pyrazines administration & dosage, SARS-CoV-2, Turkey epidemiology, COVID-19 complications, COVID-19 mortality, Hematologic Neoplasms complications, Hematologic Neoplasms mortality, Hematologic Neoplasms therapy
- Abstract
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey., Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection., Results: Forty four patients were asymptomatic at diagnosis of SARS-CoV- 2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixty-nine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use., Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.
- Published
- 2022
- Full Text
- View/download PDF
4. Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients
- Author
-
Civriz Bozdağ, Sinem, Cengiz Seval, Güldane, Yönal Hindilerden, İpek, Hindilerden, Fehmi, Andıç, Neslihan, Baydar, Mustafa, Aydın Kaynar, Lale, Toprak, Selami Koçak, Göksoy, Hasan Sami, Aydın, Berrin Balık, Demirci, Ufuk, Can, Ferda, Özkocaman, Vildan, Gündüz, Eren, Güven, Zeynep Tuğba, Özkurt, Zübeyde Nur, Demircioğlu, Sinan, Beksaç, Meral, İnce, İdris, Yılmaz, Umut, Eroğlu Küçükdiler, Hilal, Abishov, Elgün, Yavuz, Boran, Ataş, Ünal, Mutlu, Yaşa Gül, Baş, Volkan, Özkalemkaş, Fahir, Üsküdar Teke, Hava, Gürsoy, Vildan, Çelik, Serhat, Çiftçiler, Rafiye, Yağcı, Münci, Topçuoğlu, Pervin, Çeneli, Özcan, Abbasov, Hamza, Selim, Cem, Ar, Muhlis Cem, Yüce, Orhan Kemal, Sadri, Sevil, Albayrak, Canan, Demir, Ahmet Muzaffer, Güler, Nil, Keklik, Muzaffer, Terzi, Hatice, Doğan, Ali, Yegin, Zeynep Arzu, Kurt Yüksel, Meltem, Sadr, Soğol, Yavaşoğlu, İrfan, Beköz, Hüseyin Saffet, Aksu, Tekin, Maral, Senem, Erol, Veysel, Kaynar, Leylagül, İlhan, Osman, Bolaman, Ali Zahit, Gökmen Sevindik, Ömür, Akyay, Arzu, Özcan, Muhit, Gürman, Günhan, Ünal Cangül, Şule, Yavuz, Yasemin, Diz Küçükkaya, Reyhan, Özsan, Güner Hayri, and Tıp Fakültesi
- Subjects
COVID-19 ,COVID-19, SARS-CoV-2 infection, Hematological malignancy ,SARSCOV2 Infection - Abstract
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARS CoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixty nine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.
- Published
- 2021
5. Successful Hematopoietic Stem Cell Transplantation from a Donor Sibling Infected with SARS-CoV-2 Using Molnupiravir Prophylaxis.
- Author
-
Şanlı, Neslihan Mandacı, Akyol, Gülşah, Yüce, Zeynep Türe, Keklik, Muzaffer, and Ünal, Ali
- Subjects
CROSS infection prevention ,COVID-19 ,GRANULOCYTE-colony stimulating factor ,ANTIVIRAL agents ,PRE-exposure prophylaxis ,TREATMENT effectiveness ,HEMATOPOIETIC stem cell transplantation ,ORGAN donors - Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.